BAT1706 vs HD204
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: VEGF-A · full Non-Small Cell Lung Cancer pipeline
BAT1706 · Avzivi
Marketed by Bio-Thera Solutions and partners
NCT03329911 · Phase 3 · completed
This double-blind, randomized Phase 3 trial compared BAT1706, a proposed bevacizumab biosimilar, with EU-sourced Avastin, each with paclitaxel and carboplatin, in 651 patients with advanced non-squamous non-small cell lung cancer. The primary endpoint was overall response rate at week 18, tested for equivalence against pre-specified margins (risk ratio 0.75 to 1.33 or 0.73 to 1.36; risk difference -0.12 to 0.15). Both the risk ratio (1.08, 90% CI 0.94 to 1.24) and the risk difference (0.03, 95% CI -0.04 to 0.11) fell inside the margins, so the equivalence primary was met. Source: the peer-reviewed paper (Cancer Med 2023).
Reported efficacy
Overall Response Rate (Week 18): Overall response rate at week 18: 48.0% BAT1706 vs 44.5% EU-bevacizumab; risk ratio 1.08 (90% CI 0.94 to 1.24) and risk difference 0.03 (95% CI -0.04 to 0.11), both inside the pre-specified equivalence margins (Cancer Med 2023). (met)
Result source: NCT03329911
HD204
Developed by Intas Pharmaceuticals and partners
NCT03390686 · Phase 3 · active, not recruiting
This was a randomised, double-blind, active-controlled Phase 3 equivalence trial (625 patients randomised, per the sponsor) comparing HD204 with reference bevacizumab (Avastin), each with chemotherapy, in advanced non-squamous NSCLC. The primary endpoint was objective response rate at week 18, and the prespecified equivalence margin test succeeded (risk ratio 1.047, 95% CI 0.86 to 1.27), showing clinical equivalence with the reference product.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence. The sponsor's topline release reports 625 patients randomised 1:1; the registry lists 650 enrolled.
Reported efficacy
Overall Response Rate (ORR) at Week 18 (18 weeks from randomization): SAMSON-II (NCT03390686), primary endpoint ORR at week 18: HD204 48.7% vs reference bevacizumab 46.5%; risk ratio 1.047 (95% CI 0.86-1.27), within prespecified equivalence margin (met)
Result source: NCT03390686
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | BAT1706 | HD204 |
|---|---|---|
| PFS, median | —Not posted · NCT03329911 | —Trial running · NCT03390686 |
| OS, median | —Not posted · NCT03329911 | —Trial running · NCT03390686 |
| ORR | —Not posted · NCT03329911 | —Trial running · NCT03390686 |
| Duration of response, median | —Not posted · NCT03329911 | —Trial running · NCT03390686 |
PFS, median
- BAT1706
- —Not posted · NCT03329911
- HD204
- —Trial running · NCT03390686
OS, median
- BAT1706
- —Not posted · NCT03329911
- HD204
- —Trial running · NCT03390686
ORR
- BAT1706
- —Not posted · NCT03329911
- HD204
- —Trial running · NCT03390686
Duration of response, median
- BAT1706
- —Not posted · NCT03329911
- HD204
- —Trial running · NCT03390686
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. BAT1706: 3 of 4 rows · HD204: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | BAT1706 |
|---|---|
| Dropout rate | 31.7% NCT03329911 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 |
| Discontinued due to AEs | — NCT03329911 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 |
| Serious AEs | 36.6% NCT03329911 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 |
| Most frequent reported AEs | musculoskeletal and connective tissue disorders 1.5% renal and urinary disorders 0.9% hepatobiliarydisorders 0.3% NCT03329911 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
BAT1706
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BAT1706's landscape · HD204's landscape